These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 28120558)

  • 21. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
    Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Schramm AR; Stoel MG; Somi S; Hartmann M; Linssen GCM; von Birgelen C
    JACC Cardiovasc Interv; 2020 May; 13(9):1100-1109. PubMed ID: 32381186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.
    Lee SWL; Tam FCC; Lam SCC; Kong SL; Shea CP; Chan KKW; Wong MKL; Chan MPH; Wong AYT; Yung ASY; Lam YM; Zhang LW; Wu KKY; Mintz GS; Maehara A
    Circ Cardiovasc Interv; 2018 Apr; 11(4):e006034. PubMed ID: 29654119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries.
    Kwon O; Kang SH; Lee JB; Ahn JM; Lee CH; Kang DY; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
    Coron Artery Dis; 2019 Jun; 30(4):255-262. PubMed ID: 30883430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
    Kufner S; Sorges J; Mehilli J; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Rheude T; Ibrahim T; Massberg S; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):784-792. PubMed ID: 27017366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
    Talarico GP; Burzotta F; Trani C; Tommasino A; Niccoli G; Porto I; Leone AM; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):268-73. PubMed ID: 22639426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial.
    Ellert J; Christiansen EH; Maeng M; Raungaard B; Jensen SE; Kristensen SD; Veien KT; Junker AB; Jakobsen L; Aarøe J; Terkelsen CJ; Kahlert J; Villadsen AB; Bøtker HE; Jensen LO
    Catheter Cardiovasc Interv; 2019 Mar; 93(4):567-573. PubMed ID: 30244533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial.
    Koch T; Lenz T; Joner M; Xhepa E; Koppara T; Wiebe J; Coughlan JJ; Aytekin A; Ibrahim T; Kessler T; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Kufner S;
    Clin Res Cardiol; 2021 Oct; 110(10):1586-1598. PubMed ID: 34156521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial).
    Maeng M; Christiansen EH; Raungaard B; Kahlert J; Terkelsen CJ; Kristensen SD; Carstensen S; Aarøe J; Jensen SE; Villadsen AB; Lassen JF; Thim T; Eftekhari A; Veien KT; Hansen KN; Junker A; Bøtker HE; Jensen LO;
    JACC Cardiovasc Interv; 2019 Apr; 12(7):624-633. PubMed ID: 30947936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.
    Hannan EL; Zhong Y; Wu C; Walford G; Holmes DR; Jacobs AK; Stamato NJ; Venditti FJ; Sharma S; Fergus I; King SB
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1097-105. PubMed ID: 22707353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term comparison of everolimus-eluting and biolimus-eluting stents.
    Puricel S; Oberhänsli M; Guntern P; Lehmann S; Goy JJ; Arroyo D; Villeneuve H; Baeriswyl G; Stauffer JC; Togni M; Cook S
    EuroIntervention; 2013 Jul; 9(3):336-44. PubMed ID: 23482296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
    Lee HJ; Park TK; Song YB; Choi YJ; Yu CW; Yang JH; Hahn JY; Choi SH; Choi RK; Choi JH; Park JS; Kim JS; Kim TH; Jang HJ; Lee SH; Shim WH; Roh YM; Gwon HC
    Int J Cardiol; 2015 Mar; 183():190-7. PubMed ID: 25668147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.
    Grundeken MJ; Wykrzykowska JJ; Ishibashi Y; Garg S; de Vries T; Garcia-Garcia HM; Onuma Y; de Winter RJ; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Meier B; Jüni P; Yazdani A; Copt S; Windecker S; Serruys PW
    Catheter Cardiovasc Interv; 2016 Jun; 87(7):E248-60. PubMed ID: 26649651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents: A propensity score matching study.
    Kim YH; Her AY; Rha SW; Choi BG; Choi SY; Byun JK; Park Y; Kang DO; Jang WY; Kim W; Choi WG; Kang TS; Ahn J; Park SH; Park JY; Lee MH; Choi CU; Park CG; Seo HS
    Medicine (Baltimore); 2019 Aug; 98(32):e16767. PubMed ID: 31393396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
    Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26446596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries.
    D'Ascenzo F; Gaido L; Bernardi A; Saglietto A; Franzé A; Ielasi A; Trabattoni D; Di Biasi M; Infantino V; Rognoni A; Helft G; Gangor A; Latini RA; De Luca L; Mitomo S; Ugo F; Smolka G; Huczek Z; Cortese B; Capodanno D; Chieffo A; Piazza F; di Mario C; Poli A; D'Urbano M; Romeo F; Giammaria M; Varbella F; Sheiban I; Escaned J; De Ferrari GM
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):522-529. PubMed ID: 31385427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.